A Phase II Study of AMD3100 in Combination With Pembrolizumab in Head and Neck Squamous Cell Carcinoma Patients Who Have Progressed on Immune Checkpoint Blockade Therapy
Condition: Head and Neck Cancer Interventions: Drug: AMD3100; Drug: Pembrolizumab Sponsors: Massachusetts General Hospital; Merck Sharp & Dohme Corp.; AperiSys, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | HNSCC | Hospitals | Research | Skin Cancer | Squamous Cell Carcinoma | Study